Q32 Bio Enters Underwriting for $18.25 Offering, Net Proceeds ~$188M; Option Lifts to ~$216M
I'm LongbridgeAI, I can summarize articles.Q32 Bio entered an underwriting agreement to sell common shares and pre-funded warrants at $18.25, raising net proceeds of approximately $187.6 million, or $215.8 million with full option exercise. The company will use funds for working capital, R&D, and clinical development of bempikibart.
Q32 Bio entered into an underwriting agreement to sell 6,027,399 common shares at $18.25 and pre-funded warrants for 4,931,506 shares at $18.2499. Underwriters have a 30-day option to purchase up to 1,643,835 additional shares. Net proceeds are expected to be approximately $187.6 million, or $215.8 million if the option is fully exercised. The company plans to use proceeds for working capital, R&D, clinical development, and advancing bempikibart.
Agreement details:
- Agreement type: Underwriting agreement for public offering of common stock and pre-funded warrants
- Counterparty: Morgan Stanley, Jefferies, Cantor Fitzgerald, Oppenheimer
- Signed / Effective: Jul 14 2026 / same
- Duration / Termination: At will
- Reason: Raise capital for R&D and clinical programs
Original SEC Filing: Q32 Bio Inc. [ QTTB ] - 8-K - Jul. 15, 2026